This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
3 Reasons to Add Inogen (INGN) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Nevro (NVRO) Gains Following FDA Approval for Senza HFX iQ
by Zacks Equity Research
Nevro (NVRO) gets FDA approval for its next-generation SCS system, Senza HFX iQ, for treating chronic back and leg pain.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Accuray's (ARAY) New Treatment Package to Boost Patient Outcome
by Zacks Equity Research
Accuray's (ARAY) latest automated breast cancer treatment package for the Radixact System is expected to extend and improve the quality of patients' lives.
Shockwave Medical (SWAV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Shockwave Medical (SWAV) closed at $274.67 in the latest trading session, marking a +1.84% move from the prior day.
Humana (HUM) Brings Affordable MA Plan to U.S. Veterans
by Zacks Equity Research
Humana (HUM) ties up with USAA Life to develop a Medicare Advantage plan that transcends the VA system to fetch added healthcare benefits for veterans.
QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.
Thermo Fisher (TMO) Launches New TaqPath Panel in Europe
by Zacks Equity Research
This panel of Thermo Fisher (TMO), apart from detecting GI bacteria, also helps in identifying the root cause of an infection and administering the best suitable treatment fast.
Shockwave Medical (SWAV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Shockwave Medical (SWAV) closed at $267.96, marking a +1.5% move from the previous day.
3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.
Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips
by Zacks Equity Research
Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.
Top 5 Large-Cap Stocks Flying High YTD in Terrible 2022
by Nalak Das
We have narrowed our search to five large-cap stocks that have popped more than 20% year to date. These are: DINO, ENPH, LPLA, SWAV and TRGP.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) Roto-Rooter business, which is witnessing continued demand for plumbing, drain cleaning services and water restoration services.
SmileDirectClub (SDC) Hurt by Lower Spending, Margin Woe
by Zacks Equity Research
The ongoing macroeconomic challenges continue to impact SmileDirectClub's (SDC) core demographic and business spending.
Intuitive Surgical (ISRG) Up After da Vinci SP's Japan Approval
by Zacks Equity Research
Intuitive Surgical (ISRG) gains approval in Japan for its single-port robotic surgical system, da Vinci SP. It will enable surgeons to provide minimally invasive experience for complex procedures.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RFG
Shockwave Medical (SWAV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Shockwave Medical (SWAV) closed at $278.96, marking a +0.32% move from the previous day.
Haemonetics (HAE) Hospital Arm Aids, Macro Issues Persist
by Zacks Equity Research
Robust performance of Haemonetics' (HAE) Hospital business, on continued strength in the Hemostasis Management product line, instills optimism.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Veeva Systems' (VEEV) Latest Launches to Enhance Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) new offerings are expected to aid the marketing and field teams with more accurate and actionable insights into patient and HCP touchpoints.
Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWM